Dr Werner Lanthaler
Chief Executive Officer Dr Werner Lanthaler (born in 1968, Austrian citizen) was appointed Chief Executive Officer of Evotec on 06 March 2009. His current term will expire on 05 March 2021. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.
He holds a doctorate in economics from Vienna University, earned his Master’s degree from Harvard University and holds a degree in Psychology. In April 2014, Dr Werner Lanthaler became a Non-Executive Member of the Board of Directors of arGEN-X, where he also serves as Chairman of the Audit Committee. In October 2015, Dr Lanthaler became a member of the Supervisory Board of Topas Therapeutics GmbH.
Dr Mario Polywka
Chief Operating Officer Dr Mario Polywka (born in 1963, British citizen), Chief Operating Officer of Evotec, was appointed to the Management Board of Evotec AG on 28 November 2007. His current term will expire on 31 October 2019. In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.
Dr Polywka received his Bachelor’s degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994. Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.
In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd.
Dr Cord Dohrmann
Chief Scientific Officer Dr Cord Dohrmann (born in 1964, German citizen) joined Evotec AG as Chief Scientific Officer and Member of the Management Board on 01 September 2010. His current term will expire on 31 August 2019. Dr Dohrmann has spent over 20 years in biomedical research at leading academic institutions and in the biotech industry. He started his academic career in 1983 studying Biology at Tübingen University in Germany and conducting research as a DAAD scholar at Duke University, Durham, USA. Dr. Dohrmann completed his MA thesis at the Max-Planck Institute in Tübingen and subsequently enrolled at the Harvard Medical School in Boston, USA, where he received his Ph.D. in Cell and Developmental Biology in 1996.
Dr. Dohrmann continued his career as a Shiseido research fellow at the Massachusetts General Hospital in Boston before joining DeveloGen in 1999. He served the company in various management positions including CEO, leading DeveloGen from a start-up to an internationally recognised metabolic disease company with a pipeline of highly innovative preclinical and clinical products for the treatment of diabetes and related disorders. Dr. Dohrmann has been advising the European Commission, the Max-Planck-Institute as well as venture capital firms and authored and co-authored a number of publications and patents. Since December 2016, Dr Cord Dohrmann has been serving as member of the Supervisory Board of Eternygen GmbH. In June 2017, Dr Cord Dohrmann became a Non-Executive Member of the Board of Directors of FSHD Unlimited.
Chief Financial Officer Enno Spillner (born in 1970, German citizen) joined Evotec AG as Chief Financial Officer and Member of the Management Board on 18 July 2016. His current term will expire on 17 July 2019. From April 2013 until June 2016 he served as Chairman of the Management Board, Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of 4SC AG. He joined 4SC’s Management Board already in September 2005 as CFO. Before working for 4SC, Enno Spillner was Head of Finance and Controlling at BioM AG, a German regional biotech venture fund, which he joined at the beginning of 1999. In this role he was, besides finance and controlling, responsible for managing investments in the equity portfolio and also held the position of interim Managing Director at two portfolio companies; ACTIPAC Biosystems GmbH and Munich Innovative Biomaterials GmbH. In September 2001, he also assumed the position as Management Partner of BioM VC Fund. Enno Spillner began his career at MediaPlus Spezialagentur für Media GmbH, Munich.
Since 2014, he has been a Non-Executive Member of the Board of Directors and Chairman of the Audit Committee at Nanobiotix SA, Paris.
Enno Spillner earned his Dipl.-Kaufmann degree (Masters in Business) at the University of Bamberg, Germany.